On September 30, 2004, and FDA Health Advisory was issued announcing that Merck was announcing a voluntary withdrawal of Vioxx from the market due to safety concerns.  Vioxx was a commonly prescribed drug in the non-steroidal anti-inflammatory drug (NSAID) family.  It was approved by the FDA in 1999 for the management of pain and inflammation and was widely prescribed to arthritis sufferers.

A long term study of Vioxx on patients suffering from recurrent colon polyps was stopped early in September 2004 for safety reasons.  Subjects of the study using Vioxx showed an increased risk of heart attack and stroke compared to subjects taking a placebo.  Merck voluntarily pulled Vioxx from the market on September 30th.

Vioxx FDA Health Advisory Best Sellers from Amazon.com

How We Do Harm: A Doctor Breaks Ranks About Being Sick in America
by Otis Webb Brawley MD, Paul Goldberg
Amazon Price: $17.15
 

The Creative Destruction of Medicine: How the Digital Revolution Will Create ...
by Eric Topol M.D.
Amazon Price: $16.79
 

Introduction To Public Health
by Mary-Jane Schneider
Amazon Price: $61.58
 

Public Policy: Politics, Analysis, and Alternatives
by Michael E Kraft, Scott R Furlong
Amazon Price: $72.30
 

Natural Cures "They" Don't Want You To Know About
by Kevin Trudeau
Amazon Price: $7.99
 

Newsfeed display by CaRP

Vioxx FDA Health Advisory News
GN News

• FDA Allows Five Members To Sit On Yaz Birth Control Advisory Panel Despite ...
FDA Allows Five Members to Sit on Yaz Birth Control Advisory Panel Despite The Open Press press releaseOPENPRESS January 17, 2012 In December 2011, a US Food and Drug Administration FDA advisory panel voted 15 11 that the benefits of drospirenone containing birth control pills, such as Yaz and Yasmin, outweigh the risks.Ennis amp Ennis, P.A. Questions Why the FDA Allowed Five Members to Sit on Yaz all 3 news articles raquo
• In Bed With Big Pharma Industry Liaisons Raise Questions At The FDA Project ...
In Bed with Big Pharma Industry Liaisons Raise Questions at the FDAProject on Government Oversight blogIt39s hardly the first time the FDA has confronted charges of bungling conflict of interest issues. In 2004, the FDA struggled with similar criticism after members of another advisory panel voted that the painkiller Vioxx was safe enough to remain on and more raquo
• 2011The Year In Review: Trends In Health Care Enforcement The First In A JD...
2011The Year In Review: Trends in Health Care Enforcement The First in a JD Supra press releaseThis advisory reports on 2011 federal health care fraud enforcement and offers a general snapshot of the landscape that sets the stage for health care enforcement as 2012 begins. Health Care Enforcement DefenseBoston London Los Angeles New York and more raquo